Novel antibody could reduce SARS-CoV-2 transmission
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
List view / Grid view
Researchers at UC Davis Health have engineered an antibody that interferes with a critical cell mechanism to reduce transmission of the virus that causes COVID-19 in lab tests.
Using virtual screening, researchers have discovered several natural compounds that could inhibit the SARS-CoV-2 main protease.
Researchers have established a list of compounds that effect cytokine storms that could reduce mortality in COVID-19 patients.
Researchers have found that extracellular vimentin facilitates SARS-CoV-2 entry into human cells, presenting a new target.
Knowledge is power – for scientists at least – and thanks to collaborative research from a UK and German university, we now have better understanding of the SARS-CoV-2 Omicron virus, including how it behaves and effective means of treatment.
Using cryo-electron microscopy, researchers have completed the world’s first molecular analysis of the SARS-CoV-2 Omicron spike protein.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
To support disease research, Sino Biological has deposited reagents for the Omicron variant to BEI Resources.
News from the Pasteur Institute in France reports on how multi organisational efforts of numerous research institutes enabled the scientific community to gain key insight into the Omicron variant, facilitating a rapid life-saving response.
According to researchers, a new method to deliver CRISPR-Cas9 to vascular endothelial cells could be used to treat many diseases, including COVID-19.
A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
Sino Biological, Inc. has just launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world due to the high number of mutations it carries, particularly the 30-plus mutations on the Spike protein.
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.